A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus

BAYOUMY, Nervana; NADA, Hesham; EL-SHABRAWI, Mohamed

A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus

Nervana BAYOUMY, (Department of Physiology, King Saud University, Riyadh, Saudi Arabia)

Mohamed EL-SHABRAWI, (Department of Clinical and Chemical Pathology, Suze Canal University, Suze Canal, Egypt)

Hesham NADA (Department of Dermatology and Andrology, Suze Canal University, Suze Canal, Egypt)

Turkish Journal of Rheumatology(.)Archives of Rheumatology

0 0

Yıl: 2013 Cilt: 28 Sayı: 2 Sayfa Aralığı: 101 - 108 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus

Öz:

Amaç: Bu çalışmada sistemik lupus eritematöz (SLE) olan hastalarda ileri glikasyon son ürünlerinin çözünür reseptörünün (sRAGE) plazma düzeyleri değerlendirildi ve bu düzeylerin farklı klinik, laboratuvar ve tedavi parametreleri ile olan ilişkisi araştırıldı.Hastalar ve yöntemler: Çalışmaya toplam 120 SLE hastası (111 kadın, 9 erkek) ve yaş ve cinsiyet eşleştirmeli 40 sağlıklı kontrol alındı. Plazma sRAGE düzeyleri, ticari olarak satılan enzim bağlı immünosorbent test (ELISA) kiti kullanılarak ölçüldü. Plazma sRAGE düzeyleri ve SLE'nin klinik ve laboratuvar özellikleri arasındaki muhtemel ilişki de değerlendirildi. Farklı tedavi yöntemlerinin sRAGE plazma düzeyleri üzerindeki etkinliği incelendi.Bulgular: Sağlıklı kontrollere kıyasla, SLE hastalarının plazma sRAGE düzeyleri anlamlı düzeyde daha düşüktü (p=0.003). Cilt döküntüsü veya serozit olan hastaların sRAGE düzeyleri, olmayanlara kıyasla anlamlı düzeyde daha yüksekti (sırasıyla p=0.036 ve p=0.017). Daha uzun süre tedavi edilen SLE hastalarının sRAGE düzeyleri, daha kısa süreli tedavi edilenlerden daha yüksekti (p=0.000). Kortikosteroid ile tedavi edilen ve kombine tedavi edilen hastalar arasında düzey açısından anlamlı bir fark yoktu (p=0.89). sRAGE düzeyleri ve total beyaz kan hücre (WBC) sayımı (r=-0.356; p=0.003), lenfosit (r=0.341; p<0.001) ve nötrofil (r=0.289; p=0.006) arasında anlamlı negatif bir ilişki vardı.Sonuç: Çalışmamızda SLE hastalarında sRAGE plazma düzeylerinin anlamlı derecede azaldığı bulundu. Bu da, sRAGE düzeylerinin hastalığın patogenezinde muhtemel bir rol oynadığını göstermektedir.

Anahtar Kelime:

Konular: Romatoloji

Sistemik Lupus Eritematöz Olan Hastalarda İlerlemiş Glikasyon Son Ürün Düzeylerinin Çözünür Reseptörü

Öz:

Objectives: In this study, we aimed to evaluate the plasma levels of a soluble receptor for advanced glycation end products (sRAGE) in patients with systemic lupus erythematosus (SLE) and to investigate their relationship with different clinical, laboratory, and therapeutic parameters. Patients and methods: A total of 120 patients with SLE (111 females, 9 males) and 40 age- and gender-matched healthy controls were included. The plasma sRAGE levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA). The possible relationship between plasma sRAGE levels with SLE clinical and laboratory characteristics were also assessed. The effectiveness of different therapeutic modalities on plasma sRAGE levels was analyzed. Results: The SLE patients had significantly lower plasma levels of sRAGE than the healthy controls (p=0.003). The patients with a skin rash or serositis had significantly higher sRAGE levels than those without (p=0.036 and p=0.017, respectively). The SLE patients who were treated over a longer period of time showed higher levels of sRAGE than those treated for shorter periods (p=0.000). No significant difference in levels was found among the patients treated with corticosteroids and those treated with combined therapy (p=0.89). There was a significant negative correlation between the sRAGE level and the total white blood cell (WBC) count (r=-0.356; p=0.003), lymphocytes (r=0.341; p<0.001), and neutrophils (r=-0.289; p=0.006). Conclusion: We found significantly decreased plasma sRAGE levels in the SLE patients in our study. This suggests that sRAGE levels may play a role in the pathogenesis of the disease.

Anahtar Kelime:

Konular: Romatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Shirai T, Hirose S. Molecular pathogenesis of SLE. Springer Semin Immunopathol 2006;28:79-82.
Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev 2010;9:661-5. doi: 10.1016/j.autrev.2010.05.015.
Tokumoto M, Fukuda K, Shinozaki M, Kashiwagi M, Katafuchi R, Yoshida T, et al. Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane. Nephrol Dial Transplant 1999;14:2210-5.
Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99-111.
Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5.
Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006;7:774-8.
Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 2005;15:496-506.
Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101:2652-60.
Hreggvidsdottir HS, Ostberg T, Wähämaa H, Schierbeck H, Aveberger AC, Klevenvall L, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009;86:655-62. doi: 10.1189/jlb.0908548.
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502.
Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA- containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96.
Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70.
Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43.
Aringer M, Smolen JS. The role of tumor necrosis factor- alpha in systemic lupus erythematosus. Arthritis Res Ther 2008;10:202. doi: 10.1186/ar2341.
Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007;220:35-46.
Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010;37:766-75. doi: 10.3899/jrheum.090663.
Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-? and TNF-? in systemic lupus erythematosus. Rheumatol Int 2012;32:395-402. doi: 10.1007/s00296- 010-1636-6.
Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999;10:157-67.
Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care 2006;29:1420-32.
Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011;32:763-77. doi: 10.1016/j. neurobiolaging.2009.04.016.
Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637-68.
Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkötter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular- onset juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:628-37.
Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-71.
Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 2009;36:2190-4. doi: 10.3899/ jrheum.081302.
Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004;279:50019-24.
Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109.
Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 2009;48:1190-6. doi: 10.1093/ rheumatology/kep199.
Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, et al. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 2008;14:759-63. doi: 10.1177/1352458507088105.
Stewart C, Cha S, Caudle RM, Berg K, Katz J. Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren's syndrome. Rheumatol Int 2008;28:771-6. doi: 10.1007/s00296-008- 0529-4.
Nienhuis HL, de Leeuw K, Bijzet J, Smit A, Schalkwijk CG, Graaff R, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford) 2008;47:1554-8. doi: 10.1093/ rheumatology/ken302.
Ma CY, Ma JL, Jiao YL, Li JF, Wang LC, Yang QR, et al. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol 2012;75:614-22. doi: 10.1111/j.1365-3083.2012.02691.x.
Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35.
Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011 ;13:R71. doi: 10.1186/ar3332.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
Renard C, Chappey O, Wautier MP, Nagashima M, Lundh E, Morser J, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997;52:54-62.
Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010;37:766-75. doi: 10.3899/jrheum.090663.
Zong H, Madden A, Ward M, Mooney MH, Elliott CT, Stitt AW. Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem 2010;285:23137-46. doi: 10.1074/jbc.M110.133827.
Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006;47:406-11.
Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006;49:2756-62.
Bastug F, Poyrazoglu H, Gunduz Z, Tulpar S, Dusunsel R. Juvenile lupus erythematosus: fourteen years of experience. Turk J Rheumatol 2011;26:308-15.
Santilli F, Bucciarelli L, Noto D, Cefalù AB, Davì V, Ferrante E, et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007;43:1255-62.
Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:R817-24.
Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003;198:1507-15.

APA	BAYOUMY N, EL-SHABRAWI M, NADA H (2013). A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. , 101 - 108.
Chicago	BAYOUMY Nervana,EL-SHABRAWI Mohamed,NADA Hesham A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. (2013): 101 - 108.
MLA	BAYOUMY Nervana,EL-SHABRAWI Mohamed,NADA Hesham A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. , 2013, ss.101 - 108.
AMA	BAYOUMY N,EL-SHABRAWI M,NADA H A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. . 2013; 101 - 108.
Vancouver	BAYOUMY N,EL-SHABRAWI M,NADA H A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. . 2013; 101 - 108.
IEEE	BAYOUMY N,EL-SHABRAWI M,NADA H "A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus." , ss.101 - 108, 2013.
ISNAD	BAYOUMY, Nervana vd. "A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus". (2013), 101-108.

APA	BAYOUMY N, EL-SHABRAWI M, NADA H (2013). A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. Turkish Journal of Rheumatology(.)Archives of Rheumatology, 28(2), 101 - 108.
Chicago	BAYOUMY Nervana,EL-SHABRAWI Mohamed,NADA Hesham A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. Turkish Journal of Rheumatology(.)Archives of Rheumatology 28, no.2 (2013): 101 - 108.
MLA	BAYOUMY Nervana,EL-SHABRAWI Mohamed,NADA Hesham A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. Turkish Journal of Rheumatology(.)Archives of Rheumatology, vol.28, no.2, 2013, ss.101 - 108.
AMA	BAYOUMY N,EL-SHABRAWI M,NADA H A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. Turkish Journal of Rheumatology(.)Archives of Rheumatology. 2013; 28(2): 101 - 108.
Vancouver	BAYOUMY N,EL-SHABRAWI M,NADA H A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus. Turkish Journal of Rheumatology(.)Archives of Rheumatology. 2013; 28(2): 101 - 108.
IEEE	BAYOUMY N,EL-SHABRAWI M,NADA H "A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus." Turkish Journal of Rheumatology(.)Archives of Rheumatology, 28, ss.101 - 108, 2013.
ISNAD	BAYOUMY, Nervana vd. "A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus". Turkish Journal of Rheumatology(.)Archives of Rheumatology 28/2 (2013), 101-108.